scholarly journals Lung cancer risk and the inhibitors of angiotensinconverting enzyme: A mini-review of recent evidence

2019 ◽  
Vol 5 (2) ◽  
pp. e16-e16
Author(s):  
Masoumeh Asgharpour ◽  
Mohammad Ebrahimi Kalan ◽  
Seyed Hadi Mirhashemi ◽  
Amirhesam Alirezaei
Keyword(s):  
Cancer Metastasis ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Multiple Chronic Conditions ◽  
Antihypertensive Medications ◽  
Converting Enzyme Inhibitors ◽  
Arterial Blood ◽  
Carcinogenic Effects ◽  
The Subject

Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.

scholarly journals Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers

Kardiologiia ◽  
2020 ◽  
Vol 60 (4) ◽  
pp. 4-9 ◽  
Author(s):  
Yu. V. Mareev ◽  
V. Yu. Mareev
Keyword(s):  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitors ◽  
Renin Angiotensin ◽  
Receptor Blockers ◽  
Relationship Of ◽  
The Relationship

The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients’ age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system.

scholarly journals Anesthetic Management of the Hypertensive Patient: Part II

2018 ◽  
Vol 65 (3) ◽  
pp. 206-213 ◽  
Author(s):  
Russell Yancey
Keyword(s):  
Blood Pressure ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Anesthetic Management ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Antihypertensive Medications ◽  
Converting Enzyme Inhibitors ◽  
Anesthesia Providers ◽  
Treatment Of Hypertension ◽  
Important Health

Hypertension is an important health challenge that affects millions of people across the world today and is a major risk factor for cardiovascular disease. It is critical that anesthesia providers have a working knowledge of the systemic implications of hypertension. This review article will discuss the medical definitions of hypertension, the physiology of maintaining blood pressure, outpatient treatment of hypertension, anesthetic implications, and the common medications used by anesthesia providers in the treatment of hypertension. Part I provided an overview of hypertension and blood pressure regulation. In addition, drugs predominantly affecting control of hypertension via renal mechanisms such as diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and renin-inhibiting agents were discussed. In part II, the remaining major antihypertensive medications will be reviewed as well as anesthetic implications of managing patients with hypertension.

Role of angiotensin-converting enzyme inhibitors in visceral angioedema

2011 ◽  
Vol 148 (3) ◽  
pp. 377-379 ◽  
Author(s):  
Aleksandr Korniyenko ◽  
Carlos L. Alviar ◽  
Juan P. Cordova ◽  
Franz H. Messerli
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors
Sign in / Sign up

Export Citation Format

Share Document